<DOC>
	<DOCNO>NCT01458067</DOCNO>
	<brief_summary>The study consist pre-screening period determine subject 's tumor PTEN deficiencies . Subjects continue screen phase Part 1 , 2 , 3 , appropriate . In Part 1 , subject receive single dose 25 mg. After analysis 24 hour pharmacokinetic ( PK ) sample , subject may receive continuous dose receive single modify dose . In Part 2 , subject enrol dose escalation occur 3+3 design . Subjects receive single dose Day 1 , begin continuous daily dose collection 72-hour PK sample . Additional subject may enrol low dose level assessment pharmacodynamic response . In Part 3 , two tumor-specific expansion cohort enrol receive MTD BED define Part 2 . A minimum 12 maximum 20 evaluable subject enrol cohort . Interim monitor futility incorporate response data 12 subject available . In addition , 20 evaluable subject enrol Part 3 -Signal-finding Expansion Cohort MTD BED define Part 2 . All subject parts/cohorts receive daily dose withdrawal unacceptable toxicity . All subject parts/cohorts receive daily dose withdrawal unacceptable toxicity .</brief_summary>
	<brief_title>A Phase I/IIa , First Time Human , Study GSK2636771 Subjects With Advanced Solid Tumors With Phosphatase Tensin Homolog ( PTEN ) Deficiency</brief_title>
	<detailed_description>The study consist pre-screening period determine subject 's tumor PTEN deficiencies . Subjects continue screen phase Part 1 , 2 , 3 , appropriate . In Part 1 , subject receive single dose 25 mg. After analysis 24 hour pharmacokinetic ( PK ) sample , subject may receive continuous dose receive single modify dose . In Part 2 , subject enrol dose escalation occur 3+3 design . Subjects receive single dose Day 1 , begin continuous daily dose collection 72-hour PK sample . Additional subject may enrol low dose level assessment pharmacodynamic response . In Part 3 , two tumor-specific expansion cohort enrol receive MTD BED define Part 2 . A minimum 12 maximum 20 evaluable subject enrol cohort . Interim monitor futility incorporate response data 12 subject available . In addition , 20 evaluable subject enrol Part 3 -Signal-finding Expansion Cohort MTD BED define Part 2 . All subject parts/cohorts receive daily dose withdrawal unacceptable toxicity . All subject parts/cohorts receive daily dose withdrawal unacceptable toxicity .</detailed_description>
	<criteria>Prescreening Parts 1 , 2 , 3 Male female least 18 year age time sign informed consent form capable give write informed consent , include compliance requirement restriction list consent form . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain orally administer medication . Sufficient archival tumor biopsy specimen available PTEN IHC analysis , subject willing undergo fresh tumor biopsy PTEN IHC analysis . Prescreening Parts 1 2 Histologically cytologically confirm diagnosis one follow solid tumor malignancy responsive standard therapy approve curative therapy subject refuse standard therapy : Endometrial cancer ( endometriod ) , Prostate cancer , Ovarian cancer , Nonsmall cell lung cancer , Breast cancer ( ER , PR , HER2 negative ) , Gastric adenocarcinoma , Colorectal cancer , Head/neck squamous cell carcinoma , Melanoma , Glioblastoma multiformae first second recurrence ( specific disease history detail study protocol ) . Prescreening Part 3 Must tumor amenable biopsy Prescreening Part 3 CRPC cohort : prostate adenocarcinoma , surgically castrate continuously medically castrate ( great equal 8 week prior prescreening ) , persistent disease evidence disease progression follow standard therapy ( y ) include prior treatment docetaxel androgen/androgen receptor direct therapy , include enzalutamide and/or abiraterone serum testosterone level &lt; 1.7 nmol/L &lt; 50 ng/dL PSA level great equal 2.0 ng/mL For CRC cohort : CRC persistent disease evidence disease progression follow standard therapy ( y ) include multiagent chemotherapy regimen ( ) exposure oxaliplatin irinotecan . For Signalfinding Expansion Cohort : one specify tumor type responsive standard therapy , approve curative therapy , subject refuse standard therapy , include : Triple negative breast cancer ( ER , PR , HER2 negative ) , Endometriod , Gastric , Glioblastoma multiformae , Head/neck squamous cell carcinoma , Melanoma , Nonsmall cell lung cancer , Ovarian Screening Parts 1 , 2 include Prescreening criterion ( ) For Parts 1 2 , histologically cytologically confirm diagnosis one follow solid tumor malignancy responsive standard therapy approve curative therapy subject refuse standard therapy : Endometrial cancer ( endometriod ) , Prostate cancer , Ovarian cancer , Nonsmall cell lung cancer , Breast cancer ( ER , PR , HER2 negative ) , Gastric adenocarcinoma , Colorectal cancer , Head/neck squamous cell carcinoma , Melanoma , Glioblastoma multiformae first second recurrence ( specific disease history detail study protocol ) . For Part 3 , histologically cytologically confirm diagnosis one follow solid tumor malignancy responsive standard therapy approve curative therapy subject refuse standard therapy : Endometrial cancer ( endometriod ) , Prostate cancer , Gastric adenocarcinoma . All prior treatmentrelated toxicity must National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , Version 4.0 , &lt; =Grade 1 ( except alopecia ) time treatment allocation exception peripheral neuropathy , must &lt; =Grade 2 . Adequate organ system function define ANC great equal 1X10^9/L without growth factor past 7 day , hemoglobin great equal 9g/dL without transfusion past 7 day , platelet great equal 75X10^9/L without transfusion past 7 day , PT/INR PTT less equal 1.5XULN , total bilirubin less equal 1.5XULN ( isolated bilirubin &gt; 1.5XULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) , AST ALT less equal 2.5XULN ( AST/ALT 4XULN presence liver metastasis , associate elevated bilirubin ) , calculate creatinine clearance 24hour urine creatinine clearance great equal 50mL/min , cardiac ejection fraction great equal LLN echocardiography . Women childbearing potential men reproductive potential must willing practice acceptable method birth control prior start dose . Additionally , woman childbearing potential must negative serum pregnancy test within 14 day prior first dose study medication . Subjects must tumor document PTEN deficiency use analytically validate IHC assay correlative assay ( e.g. , FISH ) . Determination PTEN deficiency use archival tumor acceptable . Where archival tissue available confirm PTEN deficiency , fresh tumor sample acceptable screening , PTEN deficiency eligible . Subjects enrol part PD expansion group ( Part 2 ) must agree undergo pre ontreatment tumor biopsy . Screening Part 3 include Prescreening criterion ( ) UPC &lt; 0.2 Must continue tumor amenable biopsy Must agree undergo pretreatment ontreatment tumor biopsy Male Subjects Reproductive Potential : Subjects must agree use effective contraception throughout treatment period five day last dose study treatment . Prescreening Parts 1 , 2 , 3 Presence clinically significant GI abnormality condition may alter absorption malabsorption syndrome major resection stomach bowel . History congenital platelet function defect ( e.g. , BernardSoulier syndrome , ChediakHigashi syndrome , Glanzmann thrombasthenia , storage pool defect ) Any serious unstable preexist medical , psychiatric , condition ( include laboratory abnormality ) could interfere subject 's safety providing informed consent . Screening Parts 1 , 2 include Prescreening criterion ( ) Subject chemotherapy , radiotherapy , immunotherapy , anticancer therapy include investigational drug within 14 day prior first dose investigational drug describe study . Hormonal ( e.g. , antiandrogen ) therapy prostate cancer must stop 4 6 week prior enrolment . NOTE : Subjects prostate cancer may remain LHRH agonist . Subjects prostate cancer may remain lowdose prednisone prednisolone ( 10 mg per day ) still eligible study . Current use prohibit medication treatment GSK2636771 . Current use aspirin , clopidogrel , ticlopidine , prasugrel , ticagrelor prohibit . Anticoagulants permit subject meet PTT INR entry criterion . Their use must monitor accordance local institutional practice . Active peptic ulcer disease history abdominal fistula , GI perforation , intra abdominal abscess within 28 day prior begin study treatment . Any major surgery within last four week . Poorly control hypertension ( define systolic blood pressure &gt; =150 mmHg diastolic blood pressure &gt; 100 mmHg base mean 3 measurement approximately 2minute interval ) . NOTE : Initiation adjustment antihypertensive medication ( ) permit prior study entry . Known active infection require parenteral oral antiinfective treatment . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal cardiac disease ) . Subjects brain metastases noncentral nervous system ( CNS ) primary tumor exclude brain metastasis : Symptomatic Treated ( surgery , radiation therapy ) clinically radiographically stable one month local therapy ( assess contrast enhance magnetic resonance image [ MRI ] compute tomography [ CT ] ) , OR Asymptomatic untreated &gt; 1 cm long dimension Subjects small ( &lt; =1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy enrol . NOTE : Subjects stable ( i.e. , unchanged ) dose corticosteroid one month , corticosteroid least 2 week enrol . Subjects must also enzymeinducing anticonvulsant 4 week QTcF interval &gt; =470 msec . If screen QTcF &gt; =470 msec , repeat 2 additional time least 5 minute apart average 3 reading use determine eligibility . Other clinically significant ECG abnormality include 2nd degree ( Type II ) 3rd degree atrioventricular block . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within past 6 month . Class III IV heart failure define New York Heart Association functional classification system . Baseline cardiac troponin ( cTn ) &gt; 10 % coefficient variance ( CV ) . Known hypersensitivity component study treatment . Pregnant lactate female . Any malignancy relate human immunodeficiency virus ( HIV ) solid organ transplant ; history know HIV , history know Hepatitis B virus ( HBV ) surface antigen positivity ( subject document laboratory evidence HBV clearance may enrol ) positive Hepatitis C virus antibody confirm recombinant immunoblot assay . Screening Part 3 include Prescreening criterion ( ) Prior treatment : Anticancer therapy ( e.g. , chemotherapy delay toxicity , immunotherapy , biologic therapy chemoradiation ) within 21 day ( within 42 day prior nitrosourea mitomycin C contain therapy ) prior enrollment and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior enrollment • Investigational drug ( ) within 30 day five halflives , whichever longer , prior enrollment Current use prohibit medication ( ) requirement prohibit medication ( ) study treatment NOTE : Current use anticoagulant permit subject meet PTT INR entry criterion ( see Table 6 ) monitor accordance local institutional practice . NOTE : Subjects currently aspirin regimen use aspirin contain product ( ) time screen MUST agree discontinue aspirin aspirincontaining product ( ) least 10 day prior first dose study treatment . After study Day 22 completion assessment perform period , include tumor biopsy , aspirin regimen use aspirincontaining product ( ) may resume CRPC cohort : subject may remain LHRH agonist ( i.e. , leuprolide , goserelin , triptorelin histrelin ) , low dose prednisone prednisolone ( 10 mg/day ) , bisphosphonates ( stable dose least four week ) without interruption remain eligible study . Any unresolved great equal Grade 2 ( per CTCAE , v 4.0 ) toxicity previous anticancer therapy , except alopecia Grade 2 anemia ( hemoglobin great equal 9.0 g/dL ) Any great equal Grade 3 ( per CTCAE , v 4.0 ) electrolyte abnormality Any great equal Grade 2 ( per CTCAE , v 4.0 ) hypocalcemia ( except ionize calcium less equal Grade 1 ) , hypokalemia , hyponatremia , hypomagnesemia , symptomatic hypophosphatemia Active peptic ulcer disease history abdominal fistula , GI perforation , intraabdominal abscess within 28 day prior enrollment Previous major surgery within 28 day prior enrollment Poorly control hypertension ( define systolic blood pressure ≥150 mmHg diastolic blood pressure &gt; 100 mmHg base mean three measurement approximately 2minute interval ) NOTE : Initiation adjustment antihypertensive medication ( ) permit within 30 day prior enrollment . Known active infection require IV oral antiinfective treatment Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal cardiac disease ) Subjects brain metastasis nonCNS primary tumor exclude brain metastasis symptomatic treat ( surgery , radiation therapy ) clinically radiographically stable one month local therapy ( assess contrast enhance MRI CT ) , OR asymptomatic untreated &gt; 1 cm long dimension NOTE : Subjects small ( less equal 1 cm long dimension ) , asymptomatic brain metastasis need immediate local therapy may enrol . NOTE : Subjects receive stable ( i.e. , unchanged ) dose corticosteroid &gt; 30 day subject receive corticosteroid within 14 day prior first dose study treatment may enrol . Subjects must receive enzymeinducing anticonvulsant within 28 day prior enrollment . History evidence cardiovascular risk include follow : QTcF great equal 470 msec NOTE : If first screen QTcF great equal 470 msec , ECG repeat two additional time least five minute apart average three reading use determine eligibility . Clinically significant ECG abnormality include second degree ( Type II ) third degree AV block , history myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting , bypass grafting within past six month prior enrollment , Class III IV heart failure define NYHA functional classification system , Left ventricular ejection fraction ( LVEF ) institutional LLN , NOTE : If LLN exist institution , use LVEF &lt; 50 % , Baseline cTnI &gt; 10 % CV , NTproBNP great equal 300 pg/mL , Known cardiac metastasis Known hypersensitivity component GSK2636771 . For TumorSpecific Expansion Cohort : CRC Signalfinding Expansion Cohorts : Female subject pregnant , lactate actively breastfeed Known active : Hepatitis B surface antigen Hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>